{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:03:08Z","timestamp":1787022188179,"version":"build-2736575974"},"reference-count":69,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI141439"],"award-info":[{"award-number":["R01AI141439"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    Mucormycosis is a life-threatening fungal infection with limited treatment options and high mortality rates among immunocompromised individuals. To identify new therapeutic strategies, we screened a library of 618 antiviral compounds against\n                    <jats:italic>Rhizopus delemar<\/jats:italic>\n                    both alone and in combination with amphotericin B (AmB) to search for agents with intrinsic antifungal activity or the ability to enhance AmB\u2019s efficacy. Four candidates, IMB-301, U18666A, BLT-1, and obefazimod, showed potent in vitro effects, with three sustaining growth suppression comparable to AmB for up to 48\u2009h in time-kill assays. The hepatitis C antivirals daclatasvir (DAC) and velpatasvir (VEL) demonstrated strong synergy with AmB across\n                    <jats:italic>Mucorales<\/jats:italic>\n                    isolates, lowering AmB MICs by 4- to 32-fold (\u03a3FICI\u2009&lt;\u20090.5) and achieving fungistatic suppression of\n                    <jats:italic>R. delemar<\/jats:italic>\n                    at subinhibitory AmB concentrations (0.25 \u00b5g\/mL). Importantly, neither the standalone antivirals nor their combinations with AmB reduced Vero cell viability at concentrations exceeding 4\u201316\u2009\u00d7\u2009their MICs, while selectivity indices ranging from 8 to &gt;32 indicated favorable safety margins. These findings highlight antiviral repurposing as a promising strategy to expand treatment options for mucormycosis and support further translational development.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0342559","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T18:27:30Z","timestamp":1771439250000},"page":"e0342559","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Repurposing antiviral agents against mucormycosis"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0249-5073","authenticated-orcid":true,"given":"Ammar A.","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour M.","family":"AlKashef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0939-0458","authenticated-orcid":true,"given":"Mohamed N.","family":"Seleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"pone.0342559.ref001","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkaf004","article-title":"Clinical aspects and recent advances in fungal diseases impacting human health","volume":"80","author":"L Pagano","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"pone.0342559.ref002","doi-asserted-by":"crossref","first-page":"102325","DOI":"10.1016\/j.eclinm.2023.102325","article-title":"Social determinants of health as drivers of fungal disease","volume":"66","author":"JD Jenks","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"4","key":"pone.0342559.ref003","doi-asserted-by":"crossref","first-page":"9164","DOI":"10.1007\/s11356-022-24032-2","article-title":"Focusing COVID-19-associated mucormycosis: a major threat to immunocompromised COVID-19","volume":"30","author":"N Sharma","year":"2023","journal-title":"Environ Sci Pollut Res Int"},{"issue":"8","key":"pone.0342559.ref004","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(21)00148-8","article-title":"Mucormycosis: time to address this deadly fungal infection","volume":"2","author":"N Stone","year":"2021","journal-title":"Lancet Microbe"},{"issue":"12","key":"pone.0342559.ref005","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1086\/599105","article-title":"Recent advances in the management of mucormycosis: from bench to bedside","volume":"48","author":"B Spellberg","year":"2009","journal-title":"Clin Infect Dis"},{"key":"pone.0342559.ref006","volume-title":"Mandell, Douglas, and Bennett\u2019s principles and practice of infectious diseases","author":"JE Bennett","year":"2015","edition":"8"},{"key":"pone.0342559.ref007","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1182\/blood-2018-99-113072","article-title":"Mucormycosis Among Children with Hematological Malignancies Is Associated with High-Risk Acute Lymphoblastic Leukemia and Is Often Salvageable","volume":"132","author":"S Elitzur","year":"2018","journal-title":"Blood"},{"issue":"10","key":"pone.0342559.ref008","article-title":"Risk of Mucormycosis in Diabetes Mellitus: A Systematic Review","volume":"13","author":"M Khanna","year":"2021","journal-title":"Cureus"},{"key":"pone.0342559.ref009","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1469-0691.2009.02977.x","article-title":"The role of neutrophils in the development and outcome of zygomycosis in haematological patients","author":"L Pagano","year":"2009","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"pone.0342559.ref010","first-page":"1629","article-title":"Mucormycosis in organ and stem cell transplant recipients","volume":"54","author":"F Lanternier","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"3","key":"pone.0342559.ref011","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/jof5030057","article-title":"Necrotizing Mucormycosis of Wounds Following Combat Injuries, Natural Disasters, Burns, and Other Trauma","volume":"5","author":"TJ Walsh","year":"2019","journal-title":"J Fungi (Basel)"},{"issue":"1","key":"pone.0342559.ref012","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3390\/jof10010085","article-title":"Experimental Models to Study the Pathogenesis and Treatment of Mucormycosis","volume":"10","author":"R Ben-Ami","year":"2024","journal-title":"J Fungi (Basel)"},{"key":"pone.0342559.ref013","volume-title":"Mucormycosis","author":"JL Hernandez","year":"2025"},{"issue":"7","key":"pone.0342559.ref014","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(21)00237-8","article-title":"The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries","volume":"3","author":"M Hoenigl","year":"2022","journal-title":"Lancet Microbe"},{"issue":"6","key":"pone.0342559.ref015","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1080\/13693780802326001","article-title":"Economic burden of mucormycosis in the United States: can a vaccine be cost-effective?","volume":"47","author":"AS Ibrahim","year":"2009","journal-title":"Med Mycol"},{"issue":"10","key":"pone.0342559.ref016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010858","article-title":"Current treatments against mucormycosis and future directions","volume":"18","author":"C Smith","year":"2022","journal-title":"PLoS Pathog"},{"issue":"5","key":"pone.0342559.ref017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0324080","article-title":"HIV protease inhibitors restore amphotericin B activity against Candida","volume":"20","author":"Y Elgammal","year":"2025","journal-title":"PLoS One"},{"issue":"8","key":"pone.0342559.ref018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0308216","article-title":"Novel combinatorial approach: Harnessing HIV protease inhibitors to enhance amphotericin B\u2019s antifungal efficacy in cryptococcosis","volume":"19","author":"NM Alkashef","year":"2024","journal-title":"PLoS One"},{"issue":"1","key":"pone.0342559.ref019","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00684-20","article-title":"Potent Synergistic Interactions between Lopinavir and Azole Antifungal Drugs against Emerging Multidrug-Resistant Candida auris","volume":"65","author":"HE Eldesouky","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"pone.0342559.ref020","doi-asserted-by":"crossref","first-page":"106906","DOI":"10.1016\/j.ijantimicag.2023.106906","article-title":"Lopinavir and ritonavir act synergistically with azoles against Candida auris in vitro and in a mouse model of disseminated candidiasis","volume":"62","author":"EA Salama","year":"2023","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"pone.0342559.ref021","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01631-22","article-title":"Atazanavir Resensitizes Candida auris to Azoles","volume":"67","author":"Y Elgammal","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"pone.0342559.ref022","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/s41598-024-52012-8","article-title":"Enhanced antifungal activity of posaconazole against Candida auris by HIV protease inhibitors, atazanavir and saquinavir","volume":"14","author":"Y Elgammal","year":"2024","journal-title":"Sci Rep"},{"issue":"9","key":"pone.0342559.ref023","doi-asserted-by":"crossref","DOI":"10.1093\/mmy\/myad081","article-title":"Saquinavir potentiates itraconazole\u2019s antifungal activity against multidrug-resistant Candida auris in vitro andin vivo","volume":"61","author":"Y Elgammal","year":"2023","journal-title":"Med Mycol"},{"issue":"3","key":"pone.0342559.ref024","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved Antiviral Drugs over the Past 50 Years","volume":"29","author":"E De Clercq","year":"2016","journal-title":"Clin Microbiol Rev"},{"issue":"8","key":"pone.0342559.ref025","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.3390\/covid2080078","article-title":"Risk\/Benefit Profiles of Currently Approved Oral Antivirals for Treatment of COVID-19: Similarities and Differences","volume":"2","author":"S Corritori","year":"2022","journal-title":"COVID"},{"key":"pone.0342559.ref026","doi-asserted-by":"crossref","first-page":"173634","DOI":"10.1016\/j.ejphar.2020.173634","article-title":"Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment","volume":"889","author":"Y Wang","year":"2020","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"pone.0342559.ref027","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40263-024-01082-3","article-title":"CNS Viral Infections-What to Consider for Improving Drug Treatment: A Plea for Using Mathematical Modeling Approaches","volume":"38","author":"M Sun","year":"2024","journal-title":"CNS Drugs"},{"key":"pone.0342559.ref028","volume-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts","author":"Clinical, Laboratory Standards I","year":"2017"},{"key":"pone.0342559.ref029","volume-title":"Reference method for broth dilution antifungal susceptibility testing of filamentous fungi","author":"Clinical, Laboratory Standards I","year":"2017"},{"issue":"12","key":"pone.0342559.ref030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0314474","article-title":"Synergistic potential of lopinavir and azole combinational therapy against clinically important Aspergillus species","volume":"19","author":"N Burns","year":"2024","journal-title":"PLoS One"},{"issue":"11","key":"pone.0342559.ref031","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00556-24","article-title":"Overcoming amphotericin B resistance in Candida auris using the antiemetic drug rolapitant","volume":"68","author":"EA Salama","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"pone.0342559.ref032","doi-asserted-by":"crossref","first-page":"2322649","DOI":"10.1080\/22221751.2024.2322649","article-title":"Lansoprazole interferes with fungal respiration and acts synergistically with amphotericin B against multidrug-resistant Candida auris","volume":"13","author":"EA Salama","year":"2024","journal-title":"Emerg Microbes Infect"},{"issue":"1","key":"pone.0342559.ref033","doi-asserted-by":"crossref","first-page":"18941","DOI":"10.1038\/s41598-019-55379-1","article-title":"Identification of a Phenylthiazole Small Molecule with Dual Antifungal and Antibiofilm Activity Against Candida albicans and Candida auris","volume":"9","author":"H Mohammad","year":"2019","journal-title":"Sci Rep"},{"issue":"9","key":"pone.0342559.ref034","article-title":"In Vitro and In Vivo Antifungal Activity of Buparvaquone against Sporothrix brasiliensis","volume":"65","author":"LP Borba-Santos","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"pone.0342559.ref035","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3390\/jof7100803","article-title":"Identification of Promising Antifungal Drugs against Scedosporium and Lomentospora Species after Screening of Pathogen Box Library","volume":"7","author":"R Rollin-Pinheiro","year":"2021","journal-title":"J Fungi (Basel)"},{"issue":"4","key":"pone.0342559.ref036","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a019562","article-title":"Human Fungal Pathogens of Mucorales and Entomophthorales","volume":"5","author":"L Mendoza","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"key":"pone.0342559.ref037","unstructured":"Fungal Strain Database [Internet]. 2025 [cited 8\u201325\u20132025]. Available from: https:\/\/wi.knaw.nl\/fungal_table"},{"issue":"4","key":"pone.0342559.ref038","article-title":"Analysis of a food-borne fungal pathogen outbreak: virulence and genome of a Mucor circinelloides isolate from yogurt","volume":"5","author":"SC Lee","year":"2014","journal-title":"mBio"},{"issue":"2","key":"pone.0342559.ref039","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00310-11","article-title":"A unique chromosomal rearrangement in the Cryptococcus neoformans var. grubii type strain enhances key phenotypes associated with virulence","volume":"3","author":"CA Morrow","year":"2012","journal-title":"mBio"},{"issue":"1","key":"pone.0342559.ref040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1348-0421.2008.00083.x","article-title":"Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital","volume":"53","author":"K Satoh","year":"2009","journal-title":"Microbiol Immunol"},{"issue":"1","key":"pone.0342559.ref041","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/mmy\/myaa075","article-title":"On the lineage of Aspergillus fumigatus isolates in common laboratory use","volume":"59","author":"M Bertuzzi","year":"2021","journal-title":"Med Mycol"},{"key":"pone.0342559.ref042","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/1469-0691.12466","article-title":"Why is mucormycosis more difficult to cure than more common mycoses?","author":"A Katragkou","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"pone.0342559.ref043","article-title":"Pathogenesis of mucormycosis","author":"AS Ibrahim","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"8","key":"pone.0342559.ref044","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/myc.13256","article-title":"The double-edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis","volume":"64","author":"K Ahmadikia","year":"2021","journal-title":"Mycoses"},{"issue":"6","key":"pone.0342559.ref045","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.cmi.2023.03.008","article-title":"COVID-19-associated mucormycosis: a systematic review and meta-analysis of 958 cases","volume":"29","author":"L \u00d6zbek","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"pone.0342559.ref046","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ijid.2022.05.005","article-title":"COVID-19-Associated Mucormycosis: An Opportunistic Fungal Infection. A Case Series and Review","volume":"121","author":"AA Balushi","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"1","key":"pone.0342559.ref047","doi-asserted-by":"crossref","first-page":"7525","DOI":"10.1038\/s41598-020-64571-7","article-title":"Repurposing approach identifies pitavastatin as a potent azole chemosensitizing agent effective against azole-resistant Candida species","volume":"10","author":"HE Eldesouky","year":"2020","journal-title":"Sci Rep"},{"issue":"10","key":"pone.0342559.ref048","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s40262-019-00774-0","article-title":"Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update","volume":"58","author":"EJ Smolders","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"pone.0342559.ref049","doi-asserted-by":"crossref","first-page":"8067","DOI":"10.1038\/s41598-018-26318-3","article-title":"Identification of small molecule compounds targeting the interaction of HIV-1 Vif and human APOBEC3G by virtual screening and biological evaluation","volume":"8","author":"L Ma","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"pone.0342559.ref050","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.antiviral.2011.11.014","article-title":"U18666A, an intra-cellular cholesterol transport inhibitor, inhibits dengue virus entry and replication","volume":"93","author":"MK Poh","year":"2012","journal-title":"Antiviral Res"},{"key":"pone.0342559.ref051","article-title":"Identification of NPC1 as the target of U18666A, an inhibitor of lysosomal cholesterol export and Ebola infection","volume":"4","author":"F Lu","year":"2015","journal-title":"Elife"},{"key":"pone.0342559.ref052","doi-asserted-by":"crossref","first-page":"784856","DOI":"10.3389\/fmicb.2021.784856","article-title":"The Compound U18666A Inhibits the Intoxication of Cells by Clostridioides difficile Toxins TcdA and TcdB","volume":"12","author":"P Papatheodorou","year":"2021","journal-title":"Front Microbiol"},{"issue":"6","key":"pone.0342559.ref053","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1007\/s12035-023-03798-7","article-title":"Potential Use of the Cholesterol Transfer Inhibitor U18666A as a Potent Research Tool for the Study of Cholesterol Mechanisms in Neurodegenerative Disorders","volume":"61","author":"S Yasamineh","year":"2024","journal-title":"Mol Neurobiol"},{"key":"pone.0342559.ref054","doi-asserted-by":"crossref","DOI":"10.1016\/j.idcr.2024.e02024","article-title":"Breaking the mold: Insights into the clinical management and outcomes of rhinocerebral mucormycosis in adults","volume":"37","author":"MG Cabanilla","year":"2024","journal-title":"IDCases"},{"issue":"24","key":"pone.0342559.ref055","doi-asserted-by":"crossref","first-page":"15422","DOI":"10.1073\/pnas.222421399","article-title":"Discovery of chemical inhibitors of the selective transfer of lipids mediated by the HDL receptor SR-BI","volume":"99","author":"TJF Nieland","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"23","key":"pone.0342559.ref056","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1705234114","article-title":"Reply to Padmanabhan and Dixit: Hepatitis C virus entry inhibitors for optimally boosting direct-acting antiviral-based treatments","volume":"114","author":"H Ohashi","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pone.0342559.ref057","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.toxlet.2007.08.007","article-title":"BLT-1, a specific inhibitor of the HDL receptor SR-BI, induces a copper-dependent phenotype during zebrafish development","volume":"175","author":"D Rald\u00faa","year":"2007","journal-title":"Toxicol Lett"},{"key":"pone.0342559.ref058","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.mib.2016.05.013","article-title":"The roles of zinc and copper sensing in fungal pathogenesis","volume":"32","author":"ER Ballou","year":"2016","journal-title":"Curr Opin Microbiol"},{"key":"pone.0342559.ref059","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12977-015-0159-3","article-title":"Long lasting control of viral rebound with a new drug ABX464 targeting Rev - mediated viral RNA biogenesis","volume":"12","author":"N Campos","year":"2015","journal-title":"Retrovirology"},{"issue":"9","key":"pone.0342559.ref060","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/infdis\/jiad251","article-title":"Impact of Obefazimod on Viral Persistence, Inflammation, and Immune Activation in People With Human Immunodeficiency Virus on Suppressive Antiretroviral Therapy","volume":"228","author":"S Bernal","year":"2023","journal-title":"J Infect Dis"},{"key":"pone.0342559.ref061","article-title":"P0889 Efficacy and safety of obefazimod for the fourth and sixth year of open-label maintenance treatment in patients with moderately to severely active ulcerative colitis (UC): 2-year interim analysis after dose de-escalation to 25 mg","volume":"19","author":"S Danese","year":"2025","journal-title":"Journal of Crohn\u2019s and Colitis"},{"issue":"4","key":"pone.0342559.ref062","doi-asserted-by":"crossref","first-page":"100140","DOI":"10.1016\/j.jacig.2023.100140","article-title":"ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial","volume":"2","author":"P Giavina-Bianchi","year":"2023","journal-title":"J Allergy Clin Immunol Glob"},{"issue":"5","key":"pone.0342559.ref063","doi-asserted-by":"crossref","first-page":"249","DOI":"10.14740\/gr1662","article-title":"Gastrointestinal Mucormycosis: A Clinical Review","volume":"16","author":"Y Addasi","year":"2023","journal-title":"Gastroenterology Res"},{"issue":"11","key":"pone.0342559.ref064","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s40262-018-0645-6","article-title":"Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir\/Velpatasvir in Subjects with Hepatic Impairment","volume":"57","author":"E Mogalian","year":"2018","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"pone.0342559.ref065","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02084-16","article-title":"Preclinical Pharmacokinetics and First-in-Human Pharmacokinetics, Safety, and Tolerability of Velpatasvir, a Pangenotypic Hepatitis C Virus NS5A Inhibitor, in Healthy Subjects","volume":"61","author":"E Mogalian","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"pone.0342559.ref066","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1038\/s41598-022-09741-5","article-title":"Efficacy and safety of the sofosbuvir\/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19","volume":"12","author":"V Messina","year":"2022","journal-title":"Sci Rep"},{"issue":"8","key":"pone.0342559.ref067","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s40262-017-0624-3","article-title":"Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics","volume":"57","author":"Y Gandhi","year":"2018","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"pone.0342559.ref068","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/cid\/ciz628","article-title":"SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial","volume":"70","author":"SD1000 Research Team","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"7","key":"pone.0342559.ref069","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1093\/jac\/dkab072","article-title":"In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19","volume":"76","author":"CQ Sacramento","year":"2021","journal-title":"J Antimicrob Chemother"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0342559","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T18:27:41Z","timestamp":1771439261000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0342559"}},"subtitle":[],"editor":[{"given":"Ot\u00e1vio Augusto","family":"Chaves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":69,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0342559","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]}}}